In a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia. This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...
Read MoreType of ALL-B-lymphoblastic leukemia/lymphoma Posts on Medivizor
Looking for young patients with B-cell acute lymphoblastic leukemia to test a new T-cell therapy
In a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...
Read MoreCAR-T cell therapy and infection risk
In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies. Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...
Read MoreCAR-T cell therapy and infection risk
In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies. Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...
Read MoreBlinatumomab: A new monoclonal antibody therapy as a treatment option for relapsed B-cell ALL
In a nutshell This study examined remission rates with blinatumomab (Blincyto) treatment in patients with relapsed adult acute lymphoblastic leukemia (ALL). Researchers concluded that blinatumomab can achieve complete remission in patients with unfavorable ALL. However, this was an early-phase trial and more studies are needed. Some background...
Read More
